'More investment needed' in prostate cancer treatment

2 January 2013

Prostate cancer is the most common cancer in men, but research and funding into treating and curing it is decidedly poor, according to new figures.

It has been revealed that in a league table of research funding, prostate cancer sat in 20th place, with £417 spent on each case.

Interestingly, leukaemia gets the most funding, with £3,903 earmarked for it per case.

The Department for Health responded by saying that it intends to make prostate cancer one of its priorities to help fight cancer and drastically improve survival rates.

"Men in the UK have a problem and they don’t want to talk about it," commented Owen Sharp, chief executive of Prostate Cancer UK.

"Neither do the wives and partners who will end up supporting them, the doctors who will treat them, nor the politicians who will count on their vote. Prostate cancer is simply not on the radar."

Every year in the UK around 36,000 men are diagnosed with prostate cancer. It is most common in men aged 70 or older.

Posted by Philip Briggs

Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy above is ©Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.

Find a treatment, test or scan available at:


Find a consultant

Use one or more of the options below to search for a consultant and link through to view their Spire profile.


Let us help you

fill out this form and we will get back to you:

Please select a hospital

We can call you

Please enter your details below and we will call you back.

What is the aim of your enquiry?

Please select a hospital

If we are unable to reach you by phone, please include your email address so that we can get in touch...



© Spire Healthcare Group plc (2016)